Poxel and Sumitomo Dainippon Pharma Announce Positive Top-Line Results for Imeglimin Phase 3 Trial (TIMES 1) in Japan for the Treatment of Type 2 Diabetes
LYON, France & OSAKA, Japan--(BUSINESS WIRE)--Apr 9, 2019--POXEL SA (Euronext -- POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatme…
